

PENDERGAST et al  
Appl. No. 10/734,582  
February 16, 2007

RECEIVED  
CENTRAL FAX CENTER  
FEB 16 2007

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Withdrawn) A method of screening test compounds for the ability to prevent or treat a pathogen infection in a mammal comprising assaying said test compounds for the ability to inhibit Abl kinase activity, wherein a test compound that inhibits Abl kinase activity is a candidate agent for use in preventing or treating a pathogen infection.
2. (Withdrawn) The method according to claim 1 wherein said assay is a cell-free assay.
3. (Withdrawn) The method according to claim 2 wherein said assay comprises incubating Abl and a substrate therefor in the presence and absence of test compound and determining the amount of phosphorylation of said substrate, wherein a test compound that inhibits phosphorylation of said substrate is a candidate agent for use in preventing or treating a pathogen infection.
4. (Withdrawn) The method according to claim 3 wherein said substrate is GST-Crk.
5. (Withdrawn) The method according to claim 1 wherein said assay is a cell-based assay.

PENDERGAST et al  
Appl. No. 10/734,582  
February 16, 2007

6. (Withdrawn) The method according to claim 1 wherein said test compounds are assayed for the ability to inhibit Abl kinase activity indirectly.

7. (Original) A method of preventing or treating a pathogen infection comprising administering to a mammal in need of such prevention or treatment an inhibitor of Abl tyrosine kinase in an amount sufficient to effect said prevention or treatment.

8. (Original) The method according to claim 7 wherein said pathogen is a bacterial or viral pathogen.

9. (Original) The method according to claim 8 wherein said pathogen is a bacterial pathogen.

10. (Original) The method according to claim 9 wherein said bacterial pathogen is selected from the group consisting of *Shigella flexneri*, Enteropathogenic *E. coli* and Salmonella.

11. (Original) The method according to claim 8 wherein said pathogen is a viral pathogen.

12. (Original) The method according to claim 10 wherein said viral pathogen is vaccinia.

PENDERGAST et al  
Appl. No. 10/734,582  
February 16, 2007

13. (Original) The method according to claim 7 wherein said method is a method of treatment.
14. (Original) The method according to claim 7 wherein said method said mammal is a human.
15. (Original) The method according to claim 7 wherein said inhibitor inhibits Abl tyrosine kinase indirectly.
16. (New) The method according to claim 9 wherein the bacterial pathogen is *Shigella*.
17. (New) The method according to claim 7 wherein said pathogen requires Abl tyrosine kinase to infect mammalian cells.
18. (New) The method according to claim 17 wherein said pathogen is a bacterial pathogen.
19. (New) The method according to claim 7 wherein said pathogen catalytically activates Abl tyrosine kinase during infection of mammalian cells.
20. (New) The method according to claim 7 wherein said inhibitor of Abl tyrosine kinase is STI571.

PENDERGAST et al  
Appl. No. 10/734,582  
February 16, 2007

21. (New) The method according to claim 20 wherein said pathogen is a bacterial pathogen.

22. (New) The method according to claim 21 wherein said bacterial pathogen is *Shigella*.